PT2356090T - Formas cristalinas de fingolimod, hcl - Google Patents
Formas cristalinas de fingolimod, hclInfo
- Publication number
- PT2356090T PT2356090T PT97483507T PT09748350T PT2356090T PT 2356090 T PT2356090 T PT 2356090T PT 97483507 T PT97483507 T PT 97483507T PT 09748350 T PT09748350 T PT 09748350T PT 2356090 T PT2356090 T PT 2356090T
- Authority
- PT
- Portugal
- Prior art keywords
- crystalline forms
- fingolimod hcl
- fingolimod
- hcl
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168865 | 2008-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2356090T true PT2356090T (pt) | 2017-10-16 |
Family
ID=40521487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97483507T PT2356090T (pt) | 2008-11-11 | 2009-11-10 | Formas cristalinas de fingolimod, hcl |
Country Status (14)
Country | Link |
---|---|
US (2) | US8530522B2 (pt) |
EP (1) | EP2356090B1 (pt) |
JP (4) | JP2012508216A (pt) |
KR (2) | KR101393994B1 (pt) |
CN (3) | CN107233336A (pt) |
AU (1) | AU2009315736B2 (pt) |
BR (1) | BRPI0921826A2 (pt) |
CA (1) | CA2743232C (pt) |
ES (1) | ES2643161T3 (pt) |
MX (1) | MX2011004962A (pt) |
PL (1) | PL2356090T3 (pt) |
PT (1) | PT2356090T (pt) |
RU (2) | RU2549899C2 (pt) |
WO (1) | WO2010055028A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103228617A (zh) * | 2010-10-01 | 2013-07-31 | 斯索恩有限公司 | 制备盐酸芬戈莫德晶体的方法 |
MX2013004649A (es) | 2010-10-28 | 2013-06-05 | Mapi Pharma Ltd | Compuestos intermedios y proceso para la preparacion de fingolimod. |
WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
WO2012070059A1 (en) | 2010-11-25 | 2012-05-31 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
ES2746016T3 (es) | 2010-12-28 | 2020-03-04 | Synthon Bv | Procedimiento para la preparación de cristales de clorhidrato de fingolimod |
WO2012097330A2 (en) * | 2011-01-14 | 2012-07-19 | University Of Washington | Compositions and methods for treating degenerative muscle conditions |
WO2012146980A2 (en) | 2011-04-29 | 2012-11-01 | Dr. Reddy's Laboratories Ltd. | Preparation of fingolimod and its salts |
US9751834B2 (en) | 2011-05-26 | 2017-09-05 | Gri Bio, Inc. | Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use |
US9850265B2 (en) | 2011-05-26 | 2017-12-26 | Gri Bio, Inc. | Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use |
WO2012160188A1 (en) | 2011-05-26 | 2012-11-29 | Jado Technologies Gmbh | Hydroxy-substituted amino and ammonium derivatives and their medical use |
WO2013019872A1 (en) | 2011-08-01 | 2013-02-07 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions comprising fingolimod |
WO2013091704A1 (en) * | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
AU2014206588A1 (en) * | 2013-01-17 | 2015-07-23 | Shilpa Medicare Limited | Process for preparation of Fingolimod and its salts |
ES2964891T3 (es) * | 2013-03-05 | 2024-04-10 | Biocon Ltd | Un proceso para la preparación de compuestos de 2-amino-1,3-propanodiol y sales de los mismos |
US20160128951A1 (en) | 2013-07-29 | 2016-05-12 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
CN106860440A (zh) * | 2017-01-16 | 2017-06-20 | 南京医科大学第二附属医院 | 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用 |
CN106667981B (zh) * | 2017-01-16 | 2019-05-14 | 南京医科大学第二附属医院 | 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用 |
GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
WO2020245775A1 (en) * | 2019-06-05 | 2020-12-10 | Biocon Limited | Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
EP4353709A1 (en) | 2021-05-31 | 2024-04-17 | Shanghai Yonsun Biotechnology Co., Ltd. | Pharmaceutical salt of fingolimod, preparation method therefor, pharmaceutical composition containing same and use thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0627406B1 (en) * | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
JP4079505B2 (ja) * | 1998-04-28 | 2008-04-23 | 田辺三菱製薬株式会社 | 2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールの新規な製造法 |
EP1457478B1 (en) * | 1998-11-11 | 2017-07-19 | Novartis AG | Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols |
DK1031347T3 (da) * | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
WO2000047558A1 (fr) * | 1999-02-10 | 2000-08-17 | Welfide Corporation | Composes amide et leur utilisation medicinale |
CN1144779C (zh) * | 1999-03-11 | 2004-04-07 | 杭州中美华东制药有限公司 | 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物 |
JP4476623B2 (ja) * | 2001-06-08 | 2010-06-09 | ノバルティス アーゲー | インスリン産生細胞移植片拒絶の処置または予防 |
US20030144712A1 (en) * | 2001-12-20 | 2003-07-31 | Jackson Streeter, M.D. | Methods for overcoming organ transplant rejection |
EP1944026B1 (en) * | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
KR20050121712A (ko) | 2003-04-08 | 2005-12-27 | 노파르티스 아게 | 유기 화합물 |
CN1212308C (zh) * | 2003-07-24 | 2005-07-27 | 漆又毛 | 2-氨基-2-(2-(4-辛基苯基)乙基)-1,3-丙二醇盐酸盐的制备方法 |
CN1241903C (zh) * | 2003-10-14 | 2006-02-15 | 马启明 | 制备2-对辛基苯乙基-2-氨基丙二醇的方法 |
TWI418350B (zh) * | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ppar調節劑之醫藥組成物的用途 |
US20080221200A1 (en) * | 2005-09-30 | 2008-09-11 | Malcolm Allison | Combination of Organic Compounds |
EA013907B1 (ru) * | 2005-10-26 | 2010-08-30 | Мерк Сероно С.А. | Сульфонамидные производные и их применение для модулирования металлопротеаз |
CN1310869C (zh) * | 2005-11-22 | 2007-04-18 | 江苏吴中苏药医药开发有限责任公司 | 2-氨基-2-[2-(4-烷基苯基)乙基]-1,3-丙二醇的制备方法 |
CN100548968C (zh) * | 2006-03-01 | 2009-10-14 | 徐州师范大学 | 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法 |
US8318812B2 (en) * | 2006-06-02 | 2012-11-27 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
MX2020001259A (es) * | 2006-09-26 | 2020-03-20 | Novartis Ag | Composiciones farmaceuticas que comprenden un modulador de s1p. |
EP3011958A1 (en) * | 2008-06-20 | 2016-04-27 | Novartis AG | Paediatric compositions for treating multiple sclerosis |
CN103228617A (zh) | 2010-10-01 | 2013-07-31 | 斯索恩有限公司 | 制备盐酸芬戈莫德晶体的方法 |
-
2009
- 2009-11-10 WO PCT/EP2009/064891 patent/WO2010055028A2/en active Application Filing
- 2009-11-10 MX MX2011004962A patent/MX2011004962A/es active IP Right Grant
- 2009-11-10 JP JP2011535130A patent/JP2012508216A/ja not_active Withdrawn
- 2009-11-10 US US13/128,825 patent/US8530522B2/en active Active
- 2009-11-10 RU RU2011123371/04A patent/RU2549899C2/ru active
- 2009-11-10 KR KR1020117010560A patent/KR101393994B1/ko active IP Right Grant
- 2009-11-10 BR BRPI0921826A patent/BRPI0921826A2/pt not_active Application Discontinuation
- 2009-11-10 CA CA2743232A patent/CA2743232C/en active Active
- 2009-11-10 ES ES09748350.7T patent/ES2643161T3/es active Active
- 2009-11-10 KR KR1020137024001A patent/KR20130109254A/ko not_active Application Discontinuation
- 2009-11-10 AU AU2009315736A patent/AU2009315736B2/en active Active
- 2009-11-10 CN CN201710377640.8A patent/CN107233336A/zh active Pending
- 2009-11-10 PT PT97483507T patent/PT2356090T/pt unknown
- 2009-11-10 RU RU2015111229/04A patent/RU2015111229A/ru not_active Application Discontinuation
- 2009-11-10 CN CN200980144998XA patent/CN102209705A/zh active Pending
- 2009-11-10 CN CN201510141353.8A patent/CN104788325A/zh active Pending
- 2009-11-10 PL PL09748350T patent/PL2356090T3/pl unknown
- 2009-11-10 EP EP09748350.7A patent/EP2356090B1/en active Active
-
2013
- 2013-08-12 US US13/964,817 patent/US20140051766A1/en not_active Abandoned
-
2014
- 2014-02-06 JP JP2014020950A patent/JP2014139179A/ja not_active Withdrawn
-
2015
- 2015-09-03 JP JP2015173474A patent/JP2016028056A/ja not_active Withdrawn
-
2017
- 2017-09-07 JP JP2017172276A patent/JP2018035160A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102209705A (zh) | 2011-10-05 |
ES2643161T3 (es) | 2017-11-21 |
RU2549899C2 (ru) | 2015-05-10 |
CA2743232C (en) | 2015-12-29 |
EP2356090A2 (en) | 2011-08-17 |
EP2356090B1 (en) | 2017-07-05 |
WO2010055028A3 (en) | 2010-07-08 |
JP2016028056A (ja) | 2016-02-25 |
US8530522B2 (en) | 2013-09-10 |
US20110229501A1 (en) | 2011-09-22 |
AU2009315736B2 (en) | 2013-08-29 |
US20140051766A1 (en) | 2014-02-20 |
RU2015111229A3 (pt) | 2018-11-08 |
RU2011123371A (ru) | 2012-12-20 |
JP2014139179A (ja) | 2014-07-31 |
WO2010055028A2 (en) | 2010-05-20 |
KR20110069156A (ko) | 2011-06-22 |
RU2015111229A (ru) | 2015-11-20 |
CN107233336A (zh) | 2017-10-10 |
CN104788325A (zh) | 2015-07-22 |
BRPI0921826A2 (pt) | 2016-01-12 |
KR20130109254A (ko) | 2013-10-07 |
CA2743232A1 (en) | 2010-05-20 |
PL2356090T3 (pl) | 2017-12-29 |
JP2012508216A (ja) | 2012-04-05 |
AU2009315736A1 (en) | 2010-05-20 |
MX2011004962A (es) | 2011-05-30 |
JP2018035160A (ja) | 2018-03-08 |
KR101393994B1 (ko) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2356090T (pt) | Formas cristalinas de fingolimod, hcl | |
HK1254977A1 (zh) | 索非布韋(sofosbuvir)的結晶形式 | |
IL212073A0 (en) | Salts of fingolimod | |
GB0819182D0 (en) | Crystalline forms | |
PL2262793T3 (pl) | Formy krystaliczne nilotynibu HCL | |
ZA201105462B (en) | Crystalline insulin-conjugates | |
IL210322A (en) | A crystalline form of sitagliptin malate | |
GB201001075D0 (en) | Crystalline forms | |
EP2477628A4 (en) | PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE | |
IL216648A0 (en) | Crystalline forms of febuxostat | |
PL2963024T3 (pl) | Krystaliczne hydraty chlorku metylotioniny - część 2 | |
EP2365821A4 (en) | CRYSTALLINE FORM OF LINACLOTIDE | |
GB0902406D0 (en) | Crystalline polymorphic form | |
ZA201202405B (en) | Crystallization of 4'-epidaunorubicin x hci | |
SI2303866T1 (sl) | Kristalne oblike natrijevega rabeprazolata | |
ZA201202097B (en) | Crystalline forms of substituted pyrazolopyrimidines | |
IL200126A (en) | A new process for obtaining crystalline form v of agomalatine | |
ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
IL205451A0 (en) | Crystalline forms of tigecycline hydrochloride | |
EP2160376A4 (en) | NEW CRYSTALLINE FORMS OF ATOVAQUON | |
IL195092A0 (en) | Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate | |
IL205857A0 (en) | Processes for preparation of crystalline tigecyclline form ii | |
AU2013100530B4 (en) | Crystalline forms of fingolimod HCL | |
HU0800755D0 (en) | Novel crystalline forms | |
IL213288A0 (en) | Crystalline forms |